Axsome Therapeutics (NASDAQ:AXSM) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM) in a research report released on Monday,Benzinga reports. They currently have a $225.00 price objective on the stock.

A number of other equities research analysts have also recently issued reports on the stock. Mizuho set a $230.00 target price on shares of Axsome Therapeutics in a report on Thursday. Wells Fargo & Company raised their price target on Axsome Therapeutics from $157.00 to $193.00 and gave the stock an “overweight” rating in a report on Tuesday, January 13th. Oppenheimer reiterated an “outperform” rating and set a $220.00 price objective on shares of Axsome Therapeutics in a research note on Wednesday, December 31st. Guggenheim reissued a “buy” rating and set a $205.00 price objective on shares of Axsome Therapeutics in a report on Friday, January 2nd. Finally, TD Cowen restated a “buy” rating on shares of Axsome Therapeutics in a research note on Thursday, January 29th. Seventeen equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Axsome Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $214.18.

Axsome Therapeutics Price Performance

Shares of NASDAQ:AXSM opened at $174.76 on Monday. The firm has a market capitalization of $8.81 billion, a PE ratio of -37.42, a P/E/G ratio of 13.22 and a beta of 0.40. The company has a quick ratio of 1.50, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. The company has a 50-day moving average price of $174.45 and a two-hundred day moving average price of $144.94. Axsome Therapeutics has a twelve month low of $86.99 and a twelve month high of $191.50.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Monday, February 23rd. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.14. The company had revenue of $196.00 million for the quarter, compared to analyst estimates of $191.33 million. Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The company’s revenue for the quarter was up 65.0% on a year-over-year basis. Equities analysts forecast that Axsome Therapeutics will post -2.79 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Nick Pizzie sold 12,000 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $187.92, for a total value of $2,255,040.00. Following the transaction, the chief financial officer directly owned 42,588 shares in the company, valued at approximately $8,003,136.96. This represents a 21.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark E. Saad sold 37,577 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $165.18, for a total transaction of $6,206,968.86. Following the completion of the transaction, the director owned 10,002 shares in the company, valued at approximately $1,652,130.36. This trade represents a 78.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 308,874 shares of company stock valued at $51,390,805 over the last 90 days. 22.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Axsome Therapeutics

Several hedge funds have recently bought and sold shares of AXSM. Versant Capital Management Inc increased its holdings in shares of Axsome Therapeutics by 20,300.0% in the 3rd quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock worth $25,000 after buying an additional 203 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new position in Axsome Therapeutics in the fourth quarter worth $31,000. First Horizon Corp purchased a new position in Axsome Therapeutics in the third quarter worth $34,000. Optiver Holding B.V. increased its stake in Axsome Therapeutics by 82.3% in the third quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock valued at $35,000 after acquiring an additional 130 shares during the last quarter. Finally, Ameriflex Group Inc. purchased a new stake in Axsome Therapeutics during the fourth quarter valued at about $37,000. 81.49% of the stock is currently owned by institutional investors.

Trending Headlines about Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Q4 results beat Street estimates — Axsome reported EPS that topped consensus and reported quarterly revenue of $196M, above estimates, and 2025 full‑year revenue grew ~66% to $638.5M, driven by Auvelity and Sunosi. MSN Article
• Positive Sentiment: Analyst support: Needham reaffirmed a Buy and set a $225 price target (~28–29% upside from current levels), which can support share demand. Benzinga Note
• Neutral Sentiment: Company filed a full press release, slide deck and held the earnings call — useful for investors looking for forward guidance, commercialization detail and upcoming catalysts. Business Insider Release
• Neutral Sentiment: Earnings call and transcript are available for deeper read — helpful to assess management’s color on demand trends for Auvelity/Sunosi and development timelines. Yahoo Finance Call Summary Call Transcript
• Negative Sentiment: Valuation and pipeline concerns: a Seeking Alpha review downgraded AXSM to Hold, arguing the pipeline may be overvalued and commercial upside for key assets is uncertain — a factor that can pressure the stock despite top‑line beats. Seeking Alpha
• Negative Sentiment: Company remains loss‑making with negative margins and high leverage metrics noted in filings — investors watching profitability and cash flow may be cautious. Zacks Metrics

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.